The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1529
September 11, 2017
View Complete Issue         Table of Contents 2019 
Prasterone (Intrarosa) for Dyspareunia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Prasterone (Intrarosa) for Dyspareunia
September 11, 2017 (Issue: 1529)
The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA). Also called dehydroepiandrosterone (DHEA),...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Prasterone (Intrarosa) for Dyspareunia
Article code: 1529b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.